Press Releases
Aarkstore.com Colorectal Cancer – Executive Market Summary 2011 | PRLog
Aarkstore.com Colorectal Cancer – Executive Market Summary 2011. Dear customer Aarkstore announce a new report "Colorectal Cancer – Executive Market Summary 2011 " through its vast collection of market research report - PR11789343
Cancer Care Partners to Host Clinical Program Titled “Colorectal Cancer: New Frontiers” by
On Thursday, November 10, 2011 at 7:00 p.m. EST, Cancer Care Partners welcomes surgical oncologist, Col. Alexander Stojadinovic MD, FACS to the Michiana area for an exclusive program that will explore new frontiers in clinical decision support for colorectal cancer.
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and
Home Products & Services Contract Manufacturing GP Pharm Press Release Company Details White Papers Press Releases Regional Offices Contact Company GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg Email Article Print 30
Genetic Technology Alert. Diagnostic Detection Method for Colorectal Cancer; RNA Interference
This issue profiles a diagnostic detection method for colorectal cancer, RNA interference targeting beta tubulin, and DGKK gene associated with hypospadias. Strategic partnership details and some important patents have also been included.
New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark: January 4, 2010
New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark
Medical News: Exercise Helps Patients Beat Colorectal Cancer - in Hematology/Oncology, Colon Cancer
Men with nonmetastatic colorectal cancer who exercised regularly were less than half as likely to die from the disease as sedentary patients, researchers at the Dana-Farber Cancer Institute reported.
Myriad Genetics, Inc. - Myriad Genetics Applauds Major Health Economic Study That Supports Broad
Myriad Genetics, Inc. Logo Print Print page Email Email page PDF Download PDF Add to Briefcase « Previous Release | Next Release » Myriad Genetics Applauds Major Health Economic Study That Supports Broad Application of Genetic Testing for Hereditary Colon Cancer COLARIS is Cost
New Test from Randox Enables Rapid, Appropriate Selection of CRC Patients for Anti-EGFR Therapy |
New Test from Randox Enables Rapid, Appropriate Selection of CRC Patients for Anti-EGFR Therapy. Colorectal Cancer (CRC) is the third most common cancer worldwide. Despite recent therapeutic advances, the prognosis for metastatic CRC (mCRC) remains poor. - PR11744642
PCC Offers Webinar Series to Address Key Colorectal Cancer Issues
In a four-part, complimentary webinar series, experts will discuss barriers to screening, opportunities to lower costs, and healthcare reform. Interested parties can register at http://www.preventingcolorectalcancer.org/.
Number 2 Cancer Killer in U.S. Could Get Bumped If More People Get Screened
New CDC Vital Signs reports shows colorectal cancer cases and deaths have declined while screening has increased.
Refine by Content Type:
Refine by Source:
- www.prlog.org (14)
- www.prweb.com (7)
- www.frost.com (4)
- investor.myriad.com (1)
- www.abbott.com (1)
- www.medpagetoday.com (1)
- www.pharmaceutical-technology.com (1)
